The study, published in JAMA Internal Medicine, examined 122 U.S.-based clinical trials, involving more than 175,000 participants, for COVID-19 vaccines or treatments. Trials were published between October 2019 and February 2022.
Here are four key findings:
- Sex, race and ethnicity were reported in 89.3 percent, 77.9 percent and 71.3 percent of U.S.-based COVID-19 clinical trials, respectively, showing a gap in reporting important trial aspects.
- Female participants were underrepresented in treatment trials, at 85 percent of expected participants, but were well represented in COVID-19 prevention trials.
- Black and Asian participants were underrepresented in COVID-19 prevention trials, at 53.7 percent and 64.4 percent of expected participants, respectively, but were well represented in COVID-19 treatment trials.
- Hispanic participants were overrepresented in treatment trials, at more than 200 percent of expected participants.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
